Posts

The Ambrosia project: Aquaporin A/S visits Ateknea

/in /by

At Ateknea, we have had the opportunity to welcome Yunfeng Li and Jan Benecke from AQUAPORIN A/S at our premises to deliver them the test bench that our team has developed over the past few months.

Within the framework of SME Instrument phase 2, project AMBROSIA, our experts have designed and built-up a professional test-skid for wastewater treatment membranes. This test-skid will allow our clients assess the performance of their products under different working conditions.

Our engineers performed a training session with the AQUAPORIN team in order to introduce them to the overall functionality of the test bench, including the execution of many tests and runs of the whole process to reach client´s acceptance.

Well done AMBROSIA team!

New Born Solutions & Ateknea: EU funding success!

/in /by

New Born Solutions and Ateknea Solutions work together to democratize healthcare in Europe, with EU funding.

Great news from Brussels! We are happy to announce that New Born Solutions, a Barcelona-based startup dedicated to saving lives and democratizing healthcare via cost-effective technology that detects superficial body fluid infections without needles, has been approved for SME Instrument Phase 1 EU funding.

With the help of Ateknea’s H2020 expertise, New Born Solutions’ latest development, Neosonics, the first non-invasive screening device designed to early detection and monitoring infant meningitis, has received €50,000 in EU funding after the European Commission gave their technology the go-ahead in late April.

The Neosonics solution is innovative, simple, and revolutionary.  

There are an estimated 165 million infants at risk of meningitis each year.

Where current practice dictates that a white blood cell count be taken from a child’s spinal fluid through a lumbar puncture (which immediately triggers the need for more medication irrespective of the diagnostic results), Neosonics uses high-resolution ultrasound to non-invasively count the white blood cell in the cerebrospinal fluid below the infant’s fontanel, the region of the head where the bones are not yet closed.

It means an early diagnosis can be quickly made in a cost-effective and non-invasive way, decreasing current complications to rule out the disease in industrialized countries and infant mortality rates, especially in developing countries. By enabling early and non-invasive detection, it could vastly reduce the amount of patients with life-long disabilities and provide quantitative and reliable data for monitoring patients’ treatment response.

We at Ateknea are excited to continue working with New Born Solutions, and to see Neosonics through to the market.